Roche
MabThera shows improved leukaemia survival benefits
December 14, 2009Sales and Marketing CLL, MabThera, Roche
MabThera/Rituxan is the first treatment to show improved survival in previously untreated patients with chronic lymphocytic leukaemia (CLL), according to …
Digital Pharma: A Year in Digital (3/5)
December 14, 2009Medical Communications 2009, Roche, digi, digital pharma, year in review
A number of Roche’s own interactive educational initiatives, such as those explaining biotechnology or what it takes to develop a …
Roche invests in Spanish genome project
November 27, 2009Research and Development Roche, Spain, genomics
Roche is investing in a Spanish health authority programme to analyse the genomes of people with rare diseases.The pharma company …
Tamiflu windfall helps Roche to bumper sales growth
October 15, 2009Sales and Marketing Roche, Tamiflu
Roche has raised its sales growth prediction for 2009 on the back of a strong third quarter and record sales …
Roche divests protein expression portfolio
September 10, 2009Research and Development Roche, genomics
Roche has sold its cell-free protein expression kits business for an undisclosed sum.Berlin-based company RiNA will take control of the …
Roche and PTC sign CNS research deal
September 4, 2009Research and Development CNS, Roche
PTC Therapeutics has signed an early-stage drug discovery deal with Roche that will focus on treatments for central nervous system …
Roche’s MabThera expands licence in leukaemia
September 4, 2009Research and Development, Sales and Marketing MabThera, Roche
MabThera has been approved in Europe for use in previously treated chronic lymphocytic leukaemia, which Roche says will offer new …
Avastin shows promise in advanced breast cancer
August 20, 2009Research and Development, Sales and Marketing Roche, avastin, breast cancer
Avastin's rise continues as new data suggests it improves progression-free survival as a second line treatment for advanced breast cancer.The …
Avastin gets US approval in kidney cancer
August 4, 2009Research and Development, Sales and Marketing Roche, US, avastin
Roche's rising star Avastin has won US approval to treat the most common type of kidney cancer, the latest in …
Roche strengthened by swine flu
July 29, 2009Sales and Marketing Roche
The effect of the swine flu pandemic has boosted Roche's half-year results, adding to figures already strengthened by the company's …
Roche eyes expanded colon cancer label for Xeloda
July 20, 2009Research and Development, Sales and Marketing Roche, Xeloda
Roche is set to expand Xeloda's colon cancer indication, after a new combination of the drug was shown to increase …
Roche’s ABPI exit – a deliberate snub?
July 3, 2009Research and Development, Sales and Marketing ABPI, Roche
By Nicola O’BrienRoche is yet to explain its controversial exit from the ABPI, but the company seems determined to make …
Roche quits ABPI
June 30, 2009Research and Development, Sales and Marketing ABPI, Roche, UK
Roche is to give up its ABPI membership in a surprise move that could undermine the UK’s system of industry …
Genentech forms type I diabetes collaboration
June 11, 2009Research and Development Roche, diabetes
The deal gives the Roche-owned biotech development and marketing rights to Bayhill’s molecule BHT-3021, which is currently in phase I/II …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
